<DOC>
	<DOCNO>NCT02780323</DOCNO>
	<brief_summary>This Phase IV clinical study Compare Efficacy Safety CELBESTA® CELEBREX® Rheumatoid Arthritis Patients</brief_summary>
	<brief_title>Study Compare Efficacy Safety CELBESTA® CELEBREX® Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Thisi multi-center , double-blind , active-controlled , randomize , parallel-group clinical trial compare efficacy safety CELBESTA® CELEBREX® patient rheumatoid arthritis . The subject receive two tablet twice daily 6 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Anyone age 19 Subjects diagnose establish rheumatoid arthritis screen visit Pain great 40/100mmVAS ( Visual Analgue Scale ) washout period Patients take oral corticosteroid without dosage change ( within range prednisolone 10mg day ) least 4weeks 1 DMARDs least 3 month screen test Patients willing able provide sign informed consent nature study explain History angina pectoris congestive heart failure rest minimum activity History myocardial infarction artherosclerosis Patients coronary angioplaty coronary artery bypass graft within 1 year History stroke , transient ischemic attack hepatitis within 2 year Patients uncontrolled hypertension screen Patients take medicine might effect test result study investigator might cause excessive risk patient Intraarticular corticosteroid injection within 4 week screen biological DMARDs infliximab , adlimumab , entanercept , anakinara abatacept wihin 6 month randomization biological DMARDs rituximab within 1 year randomization History malignant tumor ( except patient whose tumor remove 's recurrence within 5 year ) Patients gastrointestinal bleeding peptic ulcer ( except scar ) within 30 day History gastroesophageal surgery antigastricsecretion surgery esophagogastrectomy ( except simple perforator surgery ) Patients severe disability GI , Kidney , Liver Blood Pregnant woman , Lactating woman Women childbering potential use adequate mean contraception History allergy COX2 inhibitor sulphonamides NSAIDs Any condition , view investigator , would interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>CELBESTA</keyword>
</DOC>